PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Amneal Pharmaceuticals, Inc. (AMRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS03168L1052
CUSIP03168L105
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic

Highlights

Market Cap$2.10B
EPS-$0.73
PE Ratio89.83
Revenue (TTM)$2.50B
Gross Profit (TTM)$791.46M
EBITDA (TTM)$535.36M
Year Range$2.15 - $6.98
Target Price$8.00
Short %0.93%
Short Ratio1.46

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Amneal Pharmaceuticals, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Amneal Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


100.00%200.00%300.00%400.00%500.00%December2024FebruaryMarchAprilMay
167.60%
531.53%
AMRX (Amneal Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Amneal Pharmaceuticals, Inc. had a return of 10.21% year-to-date (YTD) and 192.14% in the last 12 months. Over the past 10 years, Amneal Pharmaceuticals, Inc. had an annualized return of -13.34%, while the S&P 500 had an annualized return of 10.87%, indicating that Amneal Pharmaceuticals, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date10.21%11.56%
1 month23.43%7.13%
6 months49.66%17.26%
1 year192.14%26.92%
5 years (annualized)-4.12%13.56%
10 years (annualized)-13.34%10.87%

Monthly Returns

The table below presents the monthly returns of AMRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-11.86%3.18%9.78%-0.17%10.21%
202310.55%-6.36%-32.52%38.85%21.24%32.48%3.23%27.81%3.18%-8.29%11.37%40.84%205.03%
2022-8.85%2.26%-7.95%-7.43%-5.96%-12.40%11.32%-38.70%-6.91%8.91%16.36%-22.27%-59.05%
20215.25%12.06%24.86%-18.13%2.72%-9.54%-3.71%14.40%-5.32%2.81%-23.86%16.27%6.35%
2020-6.85%-14.25%-9.61%4.31%34.16%-2.26%-9.03%-5.08%-5.60%7.22%-5.05%15.70%-5.19%
2019-9.24%10.18%4.73%-9.17%-41.41%-4.91%-48.95%-30.33%13.73%6.21%22.08%28.19%-64.38%
201816.82%4.88%-4.66%-3.34%5.00%-16.87%16.82%20.50%-3.94%-16.85%-4.01%-23.60%-18.74%
2017-0.75%8.37%-11.23%11.07%8.54%5.57%20.19%11.89%-6.24%-10.59%-8.26%-0.00%25.66%
2016-12.37%-12.76%-2.05%4.15%2.40%-15.61%9.02%-23.01%-2.03%-15.19%-28.11%-8.30%-69.01%
201515.75%9.87%16.33%-3.44%3.87%-2.32%5.53%-15.48%-14.04%-1.65%27.23%-2.95%34.97%
2014-7.96%11.37%2.52%-1.02%6.16%8.03%-22.01%5.34%-3.77%22.18%10.29%-0.85%26.01%
2013-1.61%-1.59%-22.18%13.34%8.38%5.12%4.02%-1.74%0.44%-1.03%18.66%4.58%22.69%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of AMRX is 95, placing it in the top 5% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of AMRX is 9595
AMRX (Amneal Pharmaceuticals, Inc.)
The Sharpe Ratio Rank of AMRX is 9797Sharpe Ratio Rank
The Sortino Ratio Rank of AMRX is 9595Sortino Ratio Rank
The Omega Ratio Rank of AMRX is 9292Omega Ratio Rank
The Calmar Ratio Rank of AMRX is 9191Calmar Ratio Rank
The Martin Ratio Rank of AMRX is 9797Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AMRX
Sharpe ratio
The chart of Sharpe ratio for AMRX, currently valued at 3.08, compared to the broader market-2.00-1.000.001.002.003.004.003.08
Sortino ratio
The chart of Sortino ratio for AMRX, currently valued at 3.78, compared to the broader market-4.00-2.000.002.004.006.003.78
Omega ratio
The chart of Omega ratio for AMRX, currently valued at 1.45, compared to the broader market0.501.001.502.001.45
Calmar ratio
The chart of Calmar ratio for AMRX, currently valued at 1.98, compared to the broader market0.002.004.006.001.98
Martin ratio
The chart of Martin ratio for AMRX, currently valued at 19.80, compared to the broader market-10.000.0010.0020.0030.0019.80
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.34, compared to the broader market-2.00-1.000.001.002.003.004.002.34
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.31, compared to the broader market-4.00-2.000.002.004.006.003.31
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.41, compared to the broader market0.501.001.502.001.41
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.90, compared to the broader market0.002.004.006.001.90
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.93, compared to the broader market-10.000.0010.0020.0030.008.93

Sharpe Ratio

The current Amneal Pharmaceuticals, Inc. Sharpe ratio is 3.08. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Amneal Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio1.002.003.004.005.006.00December2024FebruaryMarchAprilMay
3.08
2.34
AMRX (Amneal Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Amneal Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-86.96%
0
AMRX (Amneal Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Amneal Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Amneal Pharmaceuticals, Inc. was 97.52%, occurring on Mar 28, 2023. The portfolio has not yet recovered.

The current Amneal Pharmaceuticals, Inc. drawdown is 86.96%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.52%Apr 16, 20152001Mar 28, 2023
-48.49%May 11, 2011456Mar 5, 2013317Jun 6, 2014773
-36.82%Feb 23, 200932Apr 7, 200974Jul 23, 2009106
-27.71%Jun 16, 201054Aug 31, 201030Oct 13, 201084
-25.93%Jul 2, 201423Aug 4, 201477Nov 20, 2014100

Volatility

Volatility Chart

The current Amneal Pharmaceuticals, Inc. volatility is 15.37%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%December2024FebruaryMarchAprilMay
15.37%
3.10%
AMRX (Amneal Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Amneal Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items